Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference.
Doll JA, Hira RS, Kearney KE, Kandzari DE, Riley RF, Marso SP, Grantham JA, Thompson CA, McCabe JM, Karmpaliotis D, Kirtane AJ, Lombardi W. Doll JA, et al. Among authors: kandzari de. Circ Cardiovasc Interv. 2020 Jun;13(6):e008962. doi: 10.1161/CIRCINTERVENTIONS.120.008962. Epub 2020 Jun 12. Circ Cardiovasc Interv. 2020. PMID: 32527193 Review.
Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Kirtane AJ, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2009 Oct;2(10):967-76. doi: 10.1016/j.jcin.2009.08.008. JACC Cardiovasc Interv. 2009. PMID: 19850257 Free article. Clinical Trial.
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJ; ENDEAVOR IV Investigators. Leon MB, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2009 Dec;2(12):1208-18. doi: 10.1016/j.jcin.2009.10.008. JACC Cardiovasc Interv. 2009. PMID: 20129547 Free article. Clinical Trial.
Saphenous vein graft intervention.
Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, Stone GW. Lee MS, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2011 Aug;4(8):831-43. doi: 10.1016/j.jcin.2011.05.014. JACC Cardiovasc Interv. 2011. PMID: 21851895 Free article. Review.
A percutaneous treatment algorithm for crossing coronary chronic total occlusions.
Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke MN, Karmpaliotis D, Lembo N, Pershad A, Kandzari DE, Buller CE, DeMartini T, Lombardi WL, Thompson CA. Brilakis ES, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2012 Apr;5(4):367-79. doi: 10.1016/j.jcin.2012.02.006. JACC Cardiovasc Interv. 2012. PMID: 22516392 Free article. Review.
Retrograde coronary chronic total occlusion revascularization: procedural and in-hospital outcomes from a multicenter registry in the United States.
Karmpaliotis D, Michael TT, Brilakis ES, Papayannis AC, Tran DL, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Karmpaliotis D, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2012 Dec;5(12):1273-9. doi: 10.1016/j.jcin.2012.06.025. JACC Cardiovasc Interv. 2012. PMID: 23257376 Free article.
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH Jr, Coleman PS, Stoler RC, Papadakos S, Cutlip DE, Mauri L, Kandzari DE; ENDEAVOR IV Investigators. Kirtane AJ, et al. Among authors: kandzari de. JACC Cardiovasc Interv. 2013 Apr;6(4):325-33. doi: 10.1016/j.jcin.2012.12.123. Epub 2013 Mar 20. JACC Cardiovasc Interv. 2013. PMID: 23523453 Free article. Clinical Trial.
367 results